Cargando…

Response of Pembrolizumab Alone for Non-small Cell Lung Cancer With Brain Metastasis: A Case Report and Literature Review

Treatment of brain metastases often includes surgical resection, chemotherapeutics and radiotherapy. Given the difficulty in obtaining therapeutic levels of medications within the immune-privileged central nervous system, chemotherapy as a stand-alone treatment modality for brain metastases is an un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marvin, Eric A., Furrow, Kimberley L., Kar, Ayesha, Cuoco, Joshua A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649332/ https://www.ncbi.nlm.nih.gov/pubmed/33194694 http://dx.doi.org/10.3389/fonc.2020.577159

Ejemplares similares

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer
por: Baroz, Angel R, et al.
Publicado: (2021)

Cost-Effectiveness of Pembrolizumab for the treatment of Non–Small-Cell lung cancer: A systematic review
por: Zhang, Chuan, et al.
Publicado: (2022)

Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
por: Xie, Xiao-Hong, et al.
Publicado: (2021)

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Patel, Shetal A., et al.
Publicado: (2021)

Rapidly fatal encephalitis associated with atypical lymphoid proliferations of the basal ganglia subsequent to aneurysmal subarachnoid hemorrhage
por: Kar, Ayesha, et al.
Publicado: (2019)

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%
por: Attili, Ilaria, et al.
Publicado: (2022)

Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non–small cell lung cancer after a single 200 mg administration
por: de Vries, Fenna, et al.
Publicado: (2023)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
por: Tan, Qiaoyun, et al.
Publicado: (2022)

CCKAR is a biomarker for prognosis and asynchronous brain metastasis of non-small cell lung cancer
por: Liang, Nan, et al.
Publicado: (2023)

Efficacy of Pembrolizumab and Nivolumab in Crossing the Blood Brain Barrier
por: Abid, Haisam, et al.
Publicado: (2019)

Intracardiac Metastasis From Non-Small Cell Lung Cancer
por: Verma, Vivek, et al.
Publicado: (2015)

NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis
por: Peng, Lu, et al.
Publicado: (2021)

WDR5 is a prognostic biomarker of brain metastasis from non-small cell lung cancer
por: Li, Zheng, et al.
Publicado: (2022)

Intracranial Squamous Cell Carcinoma Arising From a Cerebellopontine Angle Epidermoid Cyst Remnant Four Decades After Partial Resection
por: Cuoco, Joshua A., et al.
Publicado: (2019)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis
por: Zhu, Tianhao, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program
por: Cai, Yuanyi, et al.
Publicado: (2021)

Connexins in Lung Cancer and Brain Metastasis
por: Luo, Kai-Jun, et al.
Publicado: (2020)

Clinical features and molecular genetics associated with brain metastasis in suspected early-stage non-small cell lung cancer
por: Kim, Kangjoon, et al.
Publicado: (2023)

Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study
por: Mander, Emily Susannah, et al.
Publicado: (2023)

Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer
por: Hughes, Ryan T, et al.
Publicado: (2019)

Genomic profiling and sites of metastasis in non-small cell lung cancer
por: Chan, Kok Hoe, et al.
Publicado: (2023)

Case Report: Neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis
por: Chan, Wai-Nga, et al.
Publicado: (2022)

Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer
por: Ozawa, Yuichi, et al.
Publicado: (2020)

An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
por: Jiang, Panpan, et al.
Publicado: (2021)

Iodine-125 brachytherapy treatment for newly diagnosed brain metastasis in non-small cell lung cancer: A biocentric analysis
por: Yang, Lili, et al.
Publicado: (2022)

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
por: Liao, Jiatao, et al.
Publicado: (2021)

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
por: Ogiwara, Toshiki, et al.
Publicado: (2021)

Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study
por: Shiotsu, Shinsuke, et al.
Publicado: (2022)

Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis
por: Yang, Beibei, et al.
Publicado: (2023)

Abscopal Effect after Radiosurgery for Solitary Brain Metastasis from Non-small Cell Lung Cancer
por: Hamilton, Andrew J, et al.
Publicado: (2018)

Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review
por: Chen, Ting, et al.
Publicado: (2023)

Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis
por: Pedrosa, Rute M. S. M., et al.
Publicado: (2018)

Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients
por: Du, Xiao-Jing, et al.
Publicado: (2018)

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Prediction of bone metastasis in non-small cell lung cancer based on machine learning
por: Li, Meng-Pan, et al.
Publicado: (2023)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

Best Supportive Care Versus Whole-Brain Irradiation, Chemotherapy Alone, or WBRT Plus Chemotherapy in Patients With Brain Metastases From Small-Cell Lung Cancer: A Case-Controlled Analysis
por: Li, Hongwei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dknjq9kju8686u2gn1vp3oncmk